NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has issued a strong statement of support for the U.S. Food and Drug Administration (FDA) following the agency’s announcement that it is launching an initiative to develop a new regulatory framework specifically tailored to the scientific and practical hurdles associated with rare disease drug development and review.
The announcement marks a significant milestone for the millions of individuals and families affected by rare conditions. Released by Pam Gavin, President and Chief Executive Officer of NORD, the statement applauds FDA leadership for recognizing that extraordinary scientific breakthroughs in the field must be matched by a continuous evolution in how potential therapies are evaluated for safety and efficacy.
According to NORD, this new initiative is a direct and encouraging response to the urgent needs of the rare disease community. It follows direct advocacy efforts, including specific concerns that NORD and other prominent patient organizations raised during discussions with the Acting Commissioner earlier this year in June. For patients and families who have endured years—and in some cases generations—of waiting for viable treatment options, this institutional commitment offers tangible hope for accelerated progress.
The landscape of rare disease innovation has evolved dramatically over the past several decades. Since its founding in 1983, NORD has been a steadfast champion of policies designed to advance rare disease research and therapeutic development. That same landmark year, the passage of the Orphan Drug Act fundamentally transformed the pharmaceutical landscape by establishing vital economic and regulatory incentives to encourage the development of treatments for conditions that had long been overlooked by commercial developers.
More than forty years later, rapid scientific advancements have created unprecedented opportunities for therapeutic breakthroughs. However, this scientific progress has simultaneously underscored the pressing need for a regulatory framework that can keep pace with innovation while directly addressing the distinct, inherent challenges posed by rare diseases. Traditional approaches to clinical trial design and drug evaluation, while effective for common conditions, often prove difficult or entirely infeasible when applied to rare disorders.
Among the primary obstacles facing rare disease developers are inherently small patient populations, limited natural history data, high levels of disease heterogeneity, and a frequent absence of established biomarkers or clinically validated endpoints. A modern regulatory framework that consistently accounts for these real-world limitations—while strictly maintaining rigorous standards for overall safety and clinical effectiveness—is absolutely essential if researchers are to successfully translate laboratory discoveries into accessible, life-changing treatments.
NORD has expressed particular enthusiasm for specific elements of the FDA’s newly proposed initiative. The organization welcomes the agency’s strategic emphasis on strengthening consistency and predictability across its various review divisions, actively incorporating patient perspectives throughout the entire lifecycle of development and review, drawing upon external scientific and clinical expertise, and building the institutional knowledge necessary to support sound, forward-looking regulatory decision-making. At the same time, NORD noted that sustained leadership, adequate staffing, sufficient resources, and consistent implementation across all levels of the agency will be vital to the initiative’s ultimate success.
What makes this initiative uniquely important, according to NORD, is the profound opportunity to move beyond ad-hoc, case-by-case regulatory accommodations toward a comprehensive framework designed specifically around the complex scientific realities of rare diseases. When traditional clinical trial methodologies are simply not feasible due to low patient numbers or rapid disease progression, the medical and scientific communities require scientifically rigorous mechanisms to evaluate alternative forms of evidence. Organization leaders stress that this shift is not about lowering regulatory standards or compromising on patient safety. Rather, it is about ensuring that the methodological tools used to demonstrate safety and effectiveness are genuinely appropriate for the specific diseases and innovative treatments being evaluated.
Looking ahead, NORD has confirmed its intention to actively participate in the FDA’s upcoming stakeholder engagement process. The organization looks forward to working side-by-side with the agency and the broader rare disease community to help shape the trajectory of this important initiative.
Furthermore, NORD anticipates welcoming key FDA leadership—including the Acting Commissioner and representatives from the agency’s Rare Disease Innovation Hub—to the upcoming 2026 Rare Diseases and Orphan Products Breakthrough Summit®. The premier event is scheduled to take place from October 25 to October 27 in Washington, D.C. The summit is expected to provide an invaluable early opportunity for the rare disease community to engage in direct dialogue with FDA leadership, allowing stakeholders to explore the newly announced framework and its practical implications in much greater detail.
Ultimately, NORD emphasizes that the true measure of success for this initiative will not be found in its initial announcement, but in whether this institutional commitment translates into more consistent regulatory practices, more effective and predictable pathways for developing therapies, and, most importantly, a significantly expanded array of treatment options for people living with rare diseases.
As the process moves forward, NORD stands fully prepared to work hand-in-hand with the FDA and the wider rare disease community. The shared goal remains turning this promising policy commitment into meaningful progress and, ultimately, delivering a greater number of safe and effective treatments to the millions of individuals and families who are counting on it.
